STOCK TITAN

Armistice Capital (GCTK) reports 102,115 shares, 4.99% ownership

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

GLUCOTRACK, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report 102,115 shares, representing 4.99% of common stock, with shared voting and dispositive power over those shares. The filing states the Master Fund has the right to receive dividends or sale proceeds for the reported securities.

Positive

  • None.

Negative

  • None.

Insights

Armistice Capital reports a sub-5% position with shared control.

Armistice Capital, LLC and Steven Boyd state beneficial ownership of 102,115 shares (4.99%) with shared voting and dispositive power. The filing is an amendment to a Schedule 13G and records the ownership position as of the reported filing.

Distributions rights are attributed to the Master Fund, a client of Armistice Capital; cash‑flow treatment is described as the fund having the right to receive dividends or sale proceeds. Subsequent filings would show any material changes in position.

The filing clarifies joint reporting and attribution of rights to an investment client.

The joint filing statement under Rule 13d-1(k) designates Armistice Capital and Steven Boyd as reporting persons and allocates responsibility for future amendments. The statement preserves each party's responsibility for accuracy regarding its own information.

This is a routine disclosure of a sub-5% passive stake; monitoring future amendments will show increases above regulatory thresholds if they occur.

Shares beneficially owned 102,115 shares reported on Schedule 13G/A
Percent of class 4.99% percent of common stock
Filing date / signature date May 15, 2026 date the amendment was signed
CUSIP 45824Q804 Glucotrack common stock CUSIP
Schedule 13G/A regulatory
"Amendment No. 1; SCHEDULE 13G/A"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficially owned financial
"Amount beneficially owned: 102,115"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive power regulatory
"Shared Dispositive Power 102,115.00"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





45824Q804

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:05/15/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:05/15/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: May 15, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in GLUCOTRACK (GCTK)?

Armistice Capital and Steven Boyd report 102,115 shares, equal to 4.99% of common stock, with shared voting and dispositive power as stated in the amendment.

Who holds voting and disposition power for the reported shares?

The filing shows shared voting power of 102,115 shares and shared dispositive power of 102,115 shares for Armistice Capital and Steven Boyd.

Does the filing indicate who receives dividends or sale proceeds for the shares?

Yes. The filing states the Master Fund, an Armistice advisory client, has the right to receive dividends or proceeds from the sale of the reported securities.

When was this Schedule 13G/A signed and filed?

The joint amendment is signed and dated May 15, 2026 by Steven Boyd as Managing Member of Armistice Capital, LLC.